Novartis (NVS) stock rose moderately Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.
Entresto is Novartis' biggest moneymaker. During the December quarter, the drug generated $2.18 billion in sales. On a year-over-year basis, sales surged 33% and beat forecasts for $2.01 billion, according to FactSet.
↑ X NOW PLAYING How To Buy Stocks: IBD's Four Pillars Of InvestingBut the patent protecting Entresto will expire in July, leaving the heart failure drug open to generic competition. In fact, Novartis already expects U.S. competition for Entresto, Tasigna and Promacta to begin in mid-2025. Tasigna is a cancer drug, while Promacta treats low blood platelets.
The latter drugs are much smaller contributors to Novartis' topline. Their combined sales were $994 million in the fourth quarter.
In morning trades, Novartis stock rose 1.7% to 106.53.
Novartis wrapped the fourth quarter with core earnings of $1.98 per share and $13.15 billion in sales. Earnings jumped 29% and beat forecasts for $1.80 a share. Sales rose 15% and topped the Street's call for $12.84 billion, according to FactSet.
Novartis said it also saw strength from Kesimpta, Kisqali, Cosentyx and Leqvio in the December quarter. Kesimpta treats multiple sclerosis. Kisqali is a cancer drug, while Cosentyx treats immunology conditions. Leqvio is a cholesterol med.
Notably, Novartis shifted the timeline on its Phase 3 study of a drug called pelacarsen in patients with established cardiovascular disease and elevated Lp(a). Lp(a) or lipoprotein A is similar to "bad" LDL cholesterol. Elevated Lp(a) is considered a risk factor for cardiovascular disease. Novartis now expects its study to wrap in 2026.
"The event-driven trial was expected to readout in ~mid-25 and represents a major catalyst in the cardiometabolic space," Leerink Partners analyst Mani Foroohar said in a report.
A slew of other companies are targeting Lp(a), including Amgen (AMGN), Eli Lilly (LLY), Ionis Pharmaceuticals (IONS), Crispr Therapeutics (CRSP) and NewAmsterdam Pharma (NAMS).
YOU MAY ALSO LIKE:
Thermo Fisher Scientific Gaps Up And Nears A Buy Point On Strong Earnings Beat
Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO.
Find The Best Long-Term Investments With IBD Long-Term Leaders
IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。